# Dario Cattaneo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7905150/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 158 papers | 5,115 citations | 126708 33 h-index | 102304 66 g-index |
| 159 all docs | 159 docs citations | 159 times ranked | 6290 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples. Journal of Chemotherapy, 2022, 34, 25-34. | 0.7 | 1 |
| 2 | Population pharmacokinetics and target attainment analysis of linezolid in multidrugâ€resistant tuberculosis patients. British Journal of Clinical Pharmacology, 2022, 88, 1835-1844. | 1.1 | 11 |
| 3 | Therapeutic Drug Monitoring of Antibiotics in the Elderly: A Narrative Review. Therapeutic Drug Monitoring, 2022, 44, 75-85. | 1.0 | 7 |
| 4 | Special Issue on the Therapeutic Drug Monitoring of Anti-infective Drugs: Editorial. Therapeutic Drug Monitoring, 2022, 44, 1-2. | 1.0 | 1 |
| 5 | Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. Expert Review of Anti-Infective Therapy, 2022, 20, 997-1004. | 2.0 | 4 |
| 6 | Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report. International Journal of STD and AIDS, 2022, , 095646242210962. | 0.5 | 2 |
| 7 | Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVIDâ€19 Therapeutic Development. Clinical Pharmacology and Therapeutics, 2021, 110, 64-68. | 2.3 | 21 |
| 8 | Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience. World Journal of Biological Psychiatry, 2021, 22, 34-45. | 1.3 | 9 |
| 9 | Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. Clinical Pharmacokinetics, 2021, 60, 103-109. | 1.6 | 12 |
| 10 | Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARSâ€CoVâ€2 infection: A retrospective cohort study. Journal of Medical Virology, 2021, 93, 1421-1427. | 2.5 | 24 |
| 11 | Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. European Journal of Clinical Pharmacology, 2021, 77, 791-792. | 0.8 | 1 |
| 12 | Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients: A Call for Action?. Clinical Pharmacokinetics, 2021, 60, 603-609. | 1.6 | 12 |
| 13 | Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP. Aids, 2021, 35, 522-524. | 1.0 | 1 |
| 14 | Drugâ€"Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. Drugs and Aging, 2021, 38, 341-346. | 1.3 | 8 |
| 15 | Comment on â€œComparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6â€. Clinical Pharmacokinetics, 2021, 60, 829-831. | 1.6 | 1 |
| 16 | ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment. Pharmacogenomics Journal, 2021, 21, 586-593. | 0.9 | 8 |
| 17 | In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5. Biomedicine and Pharmacotherapy, 2021, 139, 111631. | 2.5 | 8 |
| 18 | Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens. Aids, 2021, 35, 2551-2553. | 1.0 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Association of HIV Infection with Epilepsy and Other Comorbid Conditions. AIDS and Behavior, 2020, 24, 1051-1055. | 1.4 | 3 |
| 20 | Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World Journal of Biological Psychiatry, 2020, 21, 651-657. | 1.3 | 8 |
| 21 | Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living With HIV: A Narrative Review. Therapeutic Drug Monitoring, 2020, 42, 64-74. | 1.0 | 9 |
| 22 | Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics. Therapeutic Drug Monitoring, 2020, 42, 83-92. | 1.0 | 59 |
| 23 | Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation. Therapeutic Drug Monitoring, 2020, 42, 330-334. | 1.0 | 7 |
| 24 | Drugâ€"Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs and Aging, 2020, 37, 925-933. | 1.3 | 23 |
| 25 | Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report. International Journal of STD and AIDS, 2020, 31, 1008-1010. | 0.5 | 3 |
| 26 | Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, e17-e20. | 0.9 | 5 |
| 27 | Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Blood Advances, 2020, 4, 3648-3658. | 2.5 | 24 |
| 28 | Does lopinavir really inhibit SARS-CoV-2?. Pharmacological Research, 2020, 158, 104898. | 3.1 | 29 |
| 29 | Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?. Journal of Antimicrobial Chemotherapy, 2020, 75, 2704-2706. | 1.3 | 30 |
| 30 | Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clinical Infectious Diseases, 2020, 71, 2276-2278. | 2.9 | 182 |
| 31 | Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings. Drugs in R and D, 2020, 20, 155-160. | 1.1 | 2 |
| 32 | Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement. Journal of Antimicrobial Chemotherapy, 2020, 75, 1354-1356. | 1.3 | 1 |
| 33 | Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacological Research, 2020, 157, 104826. | 3.1 | 49 |
| 34 | The management of anti-infective agents in intensive care units: the potential role of a â€˜fastâ€™ pharmacology. Expert Review of Clinical Pharmacology, 2020, 13, 355-366. | 1.3 | 14 |
| 35 | Case of Suboptimal Linezolid Exposure: Is There a Role for Pharmacogenetics?. Therapeutic Drug Monitoring, 2020, 42, 347-348. | 1.0 | 2 |
| 36 | Use of Direct Oral Anticoagulants in People Living with HIV: A Single-Center Experience. Seminars in Thrombosis and Hemostasis, 2020, 46, 999-1001. | 1.5 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | No effects of Hypericum-containing complex on dolutegravir plasma trough concentrations: a case report. European Journal of Clinical Pharmacology, 2019, 75, 1467-1468. | 0.8 | 3 |
| 38 | Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 927-935. | 1.5 | 19 |
| 39 | Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure. Frontiers in Pediatrics, 2019, 7, 309. | 0.9 | 16 |
| 40 | Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic. AIDS Reviews, 2019, 21, 40-49. | 0.5 | 15 |
| 41 | Drugâ€"drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 245-252. | 1.5 | 13 |
| 42 | R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-Î± in primary CNS lymphoma. Blood, 2019, 134, 252-262. | 0.6 | 43 |
| 43 | Effects of guggulsterones-containing thermogenic complex on elvitegravir plasma concentrations: a case report. European Journal of Clinical Pharmacology, 2019, 75, 1177-1178. | 0.8 | 4 |
| 44 | Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis. Clinical Pharmacokinetics, 2019, 58, 1345-1350. | 1.6 | 1 |
| 45 | Different effects of glucocorticoids on darunavir plasma concentrations. European Journal of Clinical Pharmacology, 2019, 75, 733-735. | 0.8 | 3 |
| 46 | Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 319-327. | 0.6 | 30 |
| 47 | Selective serotonin reuptake inhibitorsâ€™ passage into human milk of lactating women. Journal of Maternal-Fetal and Neonatal Medicine, 2019, 32, 3020-3025. | 0.7 | 9 |
| 48 | The Relevance of Drugâ€"drug Interactions in Clinical Practice: The Case of Concomitant Boosted Protease Inhibitors plus Alpha-1 Blocker Administration. Antiviral Therapy, 2018, 23, 467-469. | 0.6 | 5 |
| 49 | Dolutegravir and metformin. Aids, 2018, 32, 532-533. | 1.0 | 10 |
| 50 | Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 86-92. | 0.9 | 25 |
| 51 | Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?. Pharmacopsychiatry, 2018, 51, 270-271. | 1.7 | 10 |
| 52 | Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation. Journal of Clinical Psychopharmacology, 2018, 38, 365-369. | 0.7 | 9 |
| 53 | Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 193-201. | 0.9 | 24 |
| 54 | How relevant are the drugâ€"drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life?. Journal of Antimicrobial Chemotherapy, 2018, 73, 2271-2273. | 1.3 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Loss of Control of HIV Viremia With OTC Weightâ€Loss Drugs: A Call for Caution?. Obesity, 2018, 26, 1251-1252. | 1.5 | 8 |
| 56 | Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid. Therapeutic Drug Monitoring, 2018, 40, 140-143. | 1.0 | 9 |
| 57 | Dolutegravir Plasma Concentrations According to Companion Antiretroviral Drug: Unwanted Drug Interaction or Desirable Boosting Effect?. Antiviral Therapy, 2017, 22, 353-356. | 0.6 | 14 |
| 58 | Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 559-572. | 0.6 | 5 |
| 59 | Pharmacokinetics and Pharmacogenetics of Selective Serotonin Reuptake Inhibitors During Pregnancy: An Observational Study. Therapeutic Drug Monitoring, 2017, 39, 197-201. | 1.0 | 17 |
| 60 | Intolerance of dolutegravir-containing combination antiretroviral therapy. Aids, 2017, 31, 867-868. | 1.0 | 11 |
| 61 | How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life?. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e24-e26. | 0.9 | 18 |
| 62 | Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disoder: A Prospective Observational Study. Therapeutic Drug Monitoring, 2017, 39, 441-445. | 1.0 | 6 |
| 63 | Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. Journal of Antimicrobial Chemotherapy, 2017, 72, 1842-1844. | 1.3 | 18 |
| 64 | Is it time to revise linezolid dose in elderly patients?. European Journal of Clinical Pharmacology, 2017, 73, 1335-1336. | 0.8 | 12 |
| 65 | Dosing Colistin Properly: Letâ€™s Save â€œOur Last Resort Old Drug!â€. Clinical Infectious Diseases, 2017, 65, 870-870. | 2.9 | 10 |
| 66 | Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma. Therapeutic Drug Monitoring, 2017, 39, 531-542. | 1.0 | 4 |
| 67 | Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1183-1192. | 1.5 | 6 |
| 68 | Severe Hyperbilirubinemia in an HIV-HCVâ€“Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. Therapeutic Drug Monitoring, 2016, 38, 285-287. | 1.0 | 3 |
| 69 | Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma. Therapeutic Drug Monitoring, 2016, 38, 407-413. | 1.0 | 22 |
| 70 | Identification of Different Patterns of Dabigatran In Vivo Bioactivation in Patients on Maintenance Anticoagulation Therapy. Therapeutic Drug Monitoring, 2016, 38, 814-816. | 1.0 | 0 |
| 71 | Is there still room for therapeutic drug monitoring of linezolid in patients with tuberculosis?. European Respiratory Journal, 2016, 47, 1287-1288. | 3.1 | 3 |
| 72 | When food can make the difference: The case of elvitegravir-based co-formulation. International Journal of Pharmaceutics, 2016, 512, 301-304. | 2.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Second generation antipsychotics in â€˜real-lifeâ€™ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opinion on Drug Safety, 2016, 15, 1-8. | 1.0 | 20 |
| 74 | Therapeutic drug management of linezolid: a missed opportunity for clinicians?. International Journal of Antimicrobial Agents, 2016, 48, 728-731. | 1.1 | 48 |
| 75 | Determinants of bone diseases in tenofovir-treated HIV patients. Aids, 2016, 30, 1686-1687. | 1.0 | 1 |
| 76 | Development of an HPLCâ€"UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients. Journal of Pharmaceutical Analysis, 2016, 6, 396-403. | 2.4 | 30 |
| 77 | Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings. European Journal of Clinical Pharmacology, 2016, 72, 285-293. | 0.8 | 21 |
| 78 | Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. Journal of Antimicrobial Chemotherapy, 2016, 71, 1341-1345. | 1.3 | 5 |
| 79 | Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 533-544. | 1.5 | 52 |
| 80 | Orlistat: weight lost at cost of HIV rebound. Journal of Antimicrobial Chemotherapy, 2016, 71, 1739-1741. | 1.3 | 8 |
| 81 | Validation of an LCâ€"MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. Bioanalysis, 2016, 8, 275-283. | 0.6 | 36 |
| 82 | Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient. European Journal of Clinical Pharmacology, 2016, 72, 365-367. | 0.8 | 3 |
| 83 | Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. International Journal of Antimicrobial Agents, 2015, 45, 545-549. | 1.1 | 5 |
| 84 | Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clinical Chemistry and Laboratory Medicine, 2015, 53, 435-44. | 1.4 | 40 |
| 85 | Comparison of the Pharmacokinetics of Raltegravir Given at 2 Doses of 400 mg by Swallowing Versus One Dose of 800 mg by Chewing in Healthy Volunteers. Therapeutic Drug Monitoring, 2015, 37, 119-125. | 1.0 | 2 |
| 86 | Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring. European Journal of Clinical Pharmacology, 2015, 71, 383-385. | 0.8 | 5 |
| 87 | Prolonged inductive effect of rifampicin on linezolid exposure. European Journal of Clinical Pharmacology, 2015, 71, 643-644. | 0.8 | 10 |
| 88 | Effect of hepatitis B and C clearance on atazanavir exposure. European Journal of Clinical Pharmacology, 2015, 71, 1409-1411. | 0.8 | 1 |
| 89 | Long-term Renal Effects of Tenofovir-Disoproxil-Fumarate in Vertically HIV-Infected Children, Adolescents, and Young Adults: A 132-Month Follow-Up Study. Clinical Drug Investigation, 2015, 35, 419-426. | 1.1 | 12 |
| 90 | Is it time to revise linezolid doses in peritoneal dialysis patients? A case series. Journal of Antimicrobial Chemotherapy, 2015, 70, 2918-2920. | 1.3 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?. PLoS ONE, 2015, 10, e0123670. | 1.1 | 26 |
| 92 | Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?. BioMed Research International, 2014, 2014, 1-7. | 0.9 | 6 |
| 93 | Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers. Drug Design, Development and Therapy, 2014, 8, 411. | 2.0 | 7 |
| 94 | Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of patients infected with human immunodeficiency virus and related health care costs: a real-life study in a large cohort of patients. ClinicoEconomics and Outcomes Research, 2014, 6, 341. | 0.7 | 10 |
| 95 | Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint. Aids, 2014, 28, 2477-2480. | 1.0 | 11 |
| 96 | Lights and Shadows of the Actual European Guidelines on Bioanalytical Method Validation. Therapeutic Drug Monitoring, 2014, 36, 739-745. | 1.0 | 6 |
| 97 | Are Non-Serious Adverse Reactions to Psychiatric Drugs Really Non-Serious?. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 394-400. | 0.7 | 10 |
| 98 | Pharmacovigilance knowledge in family paediatricians. A survey study in Italy. Health Policy, 2013, 113, 216-220. | 1.4 | 21 |
| 99 | Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. International Journal of Antimicrobial Agents, 2013, 41, 586-589. | 1.1 | 99 |
| 100 | Limited sampling strategies for the estimation of atazanavir daily exposure in HIVâ€infected patients. Fundamental and Clinical Pharmacology, 2013, 27, 216-222. | 1.0 | 4 |
| 101 | Is Chewed Raltegravir an Option to Care for HIV-Infected Patients With Active Tuberculosis?. Clinical Infectious Diseases, 2013, 57, 480-481. | 2.9 | 5 |
| 102 | Tenofovir-induced Renal Tubular Dysfunction in Vertically HIV-infected Patients Associated With Polymorphisms in ABCC2, ABCC4 and ABCC10 Genes. Pediatric Infectious Disease Journal, 2013, 32, e403-e405. | 1.1 | 15 |
| 103 | Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events. PLoS ONE, 2013, 8, e80242. | 1.1 | 34 |
| 104 | Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine. CKJ: Clinical Kidney Journal, 2012, 5, 431-433. | 1.4 | 5 |
| 105 | Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing. Antimicrobial Agents and Chemotherapy, 2012, 56, 6132-6136. | 1.4 | 30 |
| 106 | Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. Journal of Antimicrobial Chemotherapy, 2012, 67, 460-464. | 1.3 | 55 |
| 107 | Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Pharmacological Research, 2012, 65, 163-167. | 3.1 | 11 |
| 108 | Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIVâ€Infected Patients. Journal of Clinical Pharmacology, 2012, 52, 440-445. | 1.0 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Atypical pharmacokinetics of atazanavir in an HIVâ€1â€infected patient. Fundamental and Clinical Pharmacology, 2012, 26, 204-206. | 1.0 | 2 |
| 110 | Perceptions and patterns of use of generic drugs among Italian Family Pediatricians: First round results of a web survey. Health Policy, 2012, 104, 247-252. | 1.4 | 40 |
| 111 | Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacological Research, 2012, 65, 472-479. | 3.1 | 40 |
| 112 | A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacological Research, 2011, 64, 210-217. | 3.1 | 36 |
| 113 | Reply to â€˜Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patientsâ€™. Aids, 2011, 25, 1012-1013. | 1.0 | 2 |
| 114 | Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Reviews, 2011, 25, 47-57. | 1.2 | 116 |
| 115 | Clinical Pharmacokinetics of Ibuprofen Arginine. Current Clinical Pharmacology, 2010, 5, 239-245. | 0.2 | 15 |
| 116 | Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. Transplantation, 2010, 89, 126-127. | 0.5 | 3 |
| 117 | Determination of Linezolid in Human Plasma by High-Performance Liquid Chromatography With Ultraviolet Detection. Therapeutic Drug Monitoring, 2010, 32, 520-524. | 1.0 | 27 |
| 118 | Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients. Therapeutic Drug Monitoring, 2010, 32, 782-786. | 1.0 | 35 |
| 119 | Coâ€administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans. British Journal of Pharmacology, 2010, 160, 1550-1560. | 2.7 | 35 |
| 120 | Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 341-358. | 2.2 | 276 |
| 121 | Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitorâ€"Free Regimen. Journal of Clinical Pharmacology, 2009, 49, 773-781. | 1.0 | 7 |
| 122 | Hepatitis C Infection and Chronic Renal Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 207-220. | 2.2 | 184 |
| 123 | ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome. Journal of the American Society of Nephrology: JASN, 2009, 20, 1404-1415. | 3.0 | 60 |
| 124 | Ibuprofenâ€"arginine generates nitric oxide and has enhanced anti-inflammatory effects. Pharmacological Research, 2009, 60, 221-228. | 3.1 | 31 |
| 125 | Population Pharmacokinetics of Mycophenolic Acid. Clinical Pharmacokinetics, 2008, 47, 827-838. | 1.6 | 79 |
| 126 | Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs, 2008, 17, 1487-1500. | 1.9 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Determination of Atazanavir in Human Plasma by High-Performance Liquid Chromatography With UV Detection. Journal of Chromatographic Science, 2008, 46, 485-489. | 0.7 | 15 |
| 128 | Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. American Journal of Nephrology, 2007, 27, 630-638. | 1.4 | 12 |
| 129 | C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141. | 0.6 | 86 |
| 130 | Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018. | 3.0 | 224 |
| 131 | Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1147-1155. | 2.2 | 53 |
| 132 | Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964. | 0.5 | 94 |
| 133 | Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. Aids, 2007, 21, 2409-2415. | 1.0 | 86 |
| 134 | Development of a CE method for the determination of mycophenolic acid in human plasma: A comparison with HPLC. Electrophoresis, 2007, 28, 3908-3914. | 1.3 | 8 |
| 135 | Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. Clinica Chimica Acta, 2006, 364, 354-358. | 0.5 | 35 |
| 136 | Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. Journal of Hepatology, 2006, 44, 837-838. | 1.8 | 5 |
| 137 | Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 643-649. | 1.0 | 3 |
| 138 | Comparison of the InnofluorÂ® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Clinical Biochemistry, 2006, 39, 1152-1159. | 0.8 | 19 |
| 139 | Cyclosporine Formulation and Kaposiâ€™s Sarcoma after Renal Transplantation. Transplantation, 2005, 80, 743-748. | 0.5 | 14 |
| 140 | Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105. | 0.2 | 4 |
| 141 | High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 816, 99-105. | 1.2 | 30 |
| 142 | Generic cyclosporine formulations: more open questions than answers. Transplant International, 2005, 18, 371-378. | 0.8 | 29 |
| 143 | Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76. | | 16 |
| 144 | Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs, 2005, 10, 747-771. | 1.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. Clinica Chimica Acta, 2005, 355, 153-164. | 0.5 | 15 |
| 146 | Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents, 2004, 14, 1553-1566. | 2.4 | 5 |
| 147 | In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. Kidney International, 2004, 65, 1084-1090. | 2.6 | 24 |
| 148 | From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. American Journal of Transplantation, 2004, 4, 299-310. | 2.6 | 58 |
| 149 | Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. American Journal of Transplantation, 2004, 4, 1345-1351. | 2.6 | 57 |
| 150 | Delayed graft function in kidney transplantation. Lancet, The, 2004, 364, 1814-1827. | 6.3 | 828 |
| 151 | Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. Personalized Medicine, 2004, 1, 53-62. | 0.8 | 1 |
| 152 | Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. Circulation, 2003, 107, 586-592. | 1.6 | 65 |
| 153 | How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy: A Multidrug Approach. Journal of the American Society of Nephrology: JASN, 2002, 13, 2898-2908. | 3.0 | 156 |
| 154 | Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 774, 187-194. | 1.2 | 25 |
| 155 | Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney International, 2002, 61, 1635-1645. | 2.6 | 103 |
| 156 | Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney International, 2002, 62, 1060-1067. | 2.6 | 214 |
| 157 | Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. Clinical Chemistry, 2001, 47, 1679-1687. | 1.5 | 56 |
| 158 | Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clinical Transplantation, 2001, 15, 402-409. | 0.8 | 75 |